Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Feb 1, 2018

(R) Lund University Bioscience AB has decided to distribute its shares in Cantargia AB

Jan 29, 2018

(R) Cantargia AB: Nomination Committee appointed for the 2018 Annual General Meeting

Jan 23, 2018

(R) Cantargia’s European patent for haematological cancers remains in force

Jan 22, 2018

(R) European Patent Office cancels oral opposition proceedings concerning Cantargia’s patent for hematological cancers

Jan 19, 2018

(R) Cantargia’s European patent for solid tumours remains in force

Jan 9, 2018

(R) European Patent Office cancels oral opposition proceedings concerning Cantargia’s patent for solid tumours

Jan 9, 2018

(R) Cantargia: Last day of trading in BTA

Jan 5, 2018

(R) Cantargia receives patent approval in China for antibody treatment against IL1RAP in solid tumours

Jan 4, 2018

(R) Cantargia receives Notice of Allowance from USPTO for expanded protection in treatment of solid tumours

Dec 21, 2017

(R) Cantargia is provided with SEK 232 million following completed share issues

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye